阿昔替尼一线治疗转移性乳头状肾细胞癌:AXIPAP II期试验结果
AXIPAP是一项法国多中心、开放标签、单臂II期试验,纳入44例未经治疗的转移性乳头状肾细胞癌患者,口服阿昔替尼5 mg每日两次。主要终点24周无进展率为45.2%,客观缓解率28.6%,中位无进展生存6.6个月,中位总生存18.9个月。毒性可控,3-4级治疗相关不良事件除高血压(27%)外罕见。
要点
- 阿昔替尼一线治疗转移性乳头状肾细胞癌显示 encouraging 疗效,尤其2型患者。
- 24周无进展率45.2%,客观缓解率28.6%,2型缓解率高于1型。
- 3-4级治疗相关不良事件除高血压(27%)外罕见,毒性可控。
核心结论
- 阿昔替尼在转移性乳头状肾细胞癌一线治疗中显示出令人鼓舞的疗效,尤其在2型患者中,毒性可控。
研究设计与样本
- 法国多中心、开放标签、单臂II期AXIPAP试验,纳入44例未经治疗的转移性乳头状肾细胞癌患者,口服阿昔替尼5 mg每日两次。
主要发现
- 24周无进展率为45.2%(95%CI 32.6%至+∞),客观缓解率28.6%(95%CI 15.7%-44.6%),其中1型7.7%、2型35.7%。
- 总体中位无进展生存6.6个月(95%CI 5.5-9.2),1型6.7个月(95%CI 5.5-9.2),2型6.2个月(95%CI 5.4-9.2)。
- 中位总生存18.9个月(95%CI 12.8-未达到)。
- 3-4级治疗相关不良事件除高血压(27%)外罕见。
临床怎么用
- 阿昔替尼可作为转移性乳头状肾细胞癌一线治疗的有趣选择,尤其2型患者。
- 推荐在该设置中进行专家病理中央审查。
- 值得进一步研究阿昔替尼联合免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Papillary renal cell carcinoma (PRCC) represents 10%-15% of renal carcinomas. No standard treatments exist for metastatic PRCC (mPRCC) patients. Axitinib is indicated as second-line treatment in metastatic clear cell renal carcinoma, and we aim to assess the efficacy of this vascular endothelial growth factor receptor inhibitor in front line for mPRCC. METHODS: This French multicentre phase II study AXIPAP enrolled untreated mPRCC patients, with measurable disease, Eastern Cooperative Oncology Group performance status ≤ 1 and adequate organ functions. PRCC had to be confirmed by histology expert central review. Axitinib was administered orally 5 mg twice daily. Primary end-point was progression-free rate at 24 weeks (24w-PFR) by central review. RESULTS: Fifty-six patients were screened, and 44 included (13 type 1, 30 type 2 and 1 non-specified). The median follow-up was 32.0 (13.1-39.9) months. The 24w-PFR was 45.2% (95% confidence interval [CI], 32.6% to +∞), the objective response rate was 28.6% (95% CI, 15.7%-44.6%) (type 1: 7.7%; type 2: 35.7%). The overall median progression free survival was 6.6 months (95% CI, 5.5-9.2), 6.7 months (95% CI, 5.5-9.2) and 6.2 months (95% CI, 5.4-9.2) for type 1 and 2, respectively. Median overall survival was 18.9 months (95% CI, 12.8-not reached). Adverse events were as expected; grade 3-4 treatment-related adverse events were rare except hypertension (27%). CONCLUSIONS: Axitinib demonstrated encouraging efficacy in mPRCC patients, especially in type 2 PRCC. Toxicity was manageable. Axitinib appears as an interesting option for first-line treatment and to be worth further investigation in combination with immunotherapy in these patients. Expert pathology review should be recommended in this setting. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02489695.
引用
- Negrier S, Rioux-Leclercq N, Ferlay C, et al. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. Eur J Cancer. 2020. PMID: 32146304. doi:10.1016/j.ejca.2020.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。